[Markers for diagnosis, prediction and prognosis of prostate cancer].
BACKGROUND
Prostate cancer is the most frequent new cancer diagnosis in the western world today. There is an urgent need to obtain validated molecular markers that can identify clinically significant prostate cancer.


METHODS
The article represents our view of the current status of molecular markers in diagnosis of prostate cancer based on literature searches (PubMed).


CONCLUSIONS
Prostate specific antigen (PSA) is a sensitive serum marker for pathology in the prostate (cancer, infection, benign hyperplasia). The level of PSA, however, is poorly correlated with grade and stage of prostate cancer. Genomic and proteomic methodology has recently been used to discover more then 200 putative new markers for prostate cancer like alpha-methylacyl CoA racemase (AMACR), hepsin, glutathione S-transferase pi, EZH2 and DD3(PCA3). To date, none of these markers have been adequately validated for clinical use. Knowledge about the role of these candidates in prostate cancer biology and evaluation of their correlation to clinical parameters will be of importance in the validation process.
Taskén
Kristin Austlid
KA
Fakultetsdivisjonen Aker, Universitetet i Oslo, og Seksjon for urologisk molekylaerbiologi, Oslo Urologiske Universitetsklinikk (OUU), Aker universitetssykehus, Trondheimsveien 235, 0514 Oslo. k.a.tasken@medisin.uio.no
Angelsen
Anders
A
Svindland
Aud
A
Eide
Turid
T
Berge
Viktor
V
Wahlquist
Rolf
R
Karlsen
Steinar
S
D014408:Biomarkers, Tumor / Q000032:analysis*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D025202:Molecular Diagnostic Techniques; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen